E-LIB Suche - Ergebnisse für: Hoffman, Ronald - Sprache DE

OpenAccess-Volltexte X

Personensuche X

Sortierung: Relevanz

Sortierung: Jahr

1

Biological drivers of clinical phenotype in myelofibrosis:

Mascarenhas, John ; Gleitz, Hélène F. E ; Schneider, Rebekka K...
info:eu-repo/semantics/altIdentifier/doi/10.18154/RWTH-2022-11553. , 2023

Link: https://publications.rwt..

2

S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELO..:

Wang, Xiaoli ; Hu, Cing Siang ; Davis, Andrew..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428503/. , 2023

Link: http://www.ncbi.nlm.nih...

3

An MDM2 Degrader for Treatment of Acute Leukemias:

Marcellino, Bridget K ; Yang, Xiaobao ; Kaniskan, H Ümit...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899314/. , 2023

Link: http://www.ncbi.nlm.nih...

4

P1016: RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV)..:

Kuykendall, Andrew ; Kremyanskaya, Marina ; Ginzburg, Yelena...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431246/. , 2023

Link: http://www.ncbi.nlm.nih...

5

MANIFEST: Pelabresib in Combination With Ruxolitinib for Ja..:

Mascarenhas, John ; Kremyanskaya, Marina ; Patriarca, Andrea...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642902/. , 2023

Link: http://www.ncbi.nlm.nih...

6

PB2195: CHARACTERISTICS OF PATIENTS WITH POLYCYTHEMIA VERA:..:

Hoffman, Ronald ; Modi, Nishit ; Koschmieder, Steffen...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428907/. , 2023

Link: http://www.ncbi.nlm.nih...

7

Targeting CHAF1B Enhances IFN Activity against Myeloprolife..:

Saleiro, Diana ; Kosciuczuk, Ewa M ; Fischietti, Mariafausta...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231401/. , 2023

Link: http://www.ncbi.nlm.nih...

8

The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development ..:

Verachi, Paola ; Gobbo, Francesca ; Martelli, Fabrizio...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982152/. , 2022

Link: http://www.ncbi.nlm.nih...

9

Symptom Burden and Quality of Life in Patients With High-Ri..:

Mazza, Gina L ; Mead-Harvey, Carolyn ; Mascarenhas, John...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098160/. , 2022

Link: http://www.ncbi.nlm.nih...

10

International Consensus Classification of Myeloid Neoplasms..:

Arber, Daniel A ; Orazi, Attilio ; Hasserjian, Robert P...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479031/. , 2022

Link: http://www.ncbi.nlm.nih...

11

Megakaryocytes Are Regulators of the Tumor Microenvironment..:

Varricchio, Lilian ; Hoffman, Ronald
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130548/. , 2022

Link: http://www.ncbi.nlm.nih...

12

IL-13/IL-4 signaling contributes to fibrotic progression of..:

Melo-Cardenas, Johanna ; Bezavada, Lavanya ; Crawford, Jeremy Chase...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813832/. , 2022

Link: http://www.ncbi.nlm.nih...

13

A Randomized, Phase 3, Trial of Interferon-α versus Hydroxy..:

Mascarenhas, John ; Kosiorek, Heidi E ; Prchal, Josef T...
info:eu-repo/semantics/altIdentifier/pmid/35007321. , 2022

Link: http://hdl.handle.net/24..

14

Combined Drug Targeting of p53-dependent and -independent P..:

Lu, Min ; Xia, Lijuan ; Elmansy, Nada...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885407/. , 2022

Link: http://www.ncbi.nlm.nih...

15

Biological drivers of clinical phenotype in myelofibrosis:

Mascarenhas, John ; Gleitz, Hélène F. E ; Chifotides, Helen T...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898039/. , 2022

Link: http://www.ncbi.nlm.nih...

1-15